Baseline characteristics and survival analysis of patients with prostate cancer in the Fourth Hospital of Hebei Medical University

樊　博; 齐　盼; 苏建志; 卫书飞; 张　轩; 张爱莉

doi:10.19401/j.cnki.1007-3639.2020.08.009

您当前的位置：

首页 >

文章列表页 >

Baseline characteristics and survival analysis of patients with prostate cancer in the Fourth Hospital of Hebei Medical University

更新时间：2026-01-27

- Baseline characteristics and survival analysis of patients with prostate cancer in the Fourth Hospital of Hebei Medical University
- China Oncology Vol. 30, Issue 8, Pages: 620-625(2020)
- 作者机构：
  
  1. 河北医科大学第四医院泌尿外科,河北,石家庄,050000
  2. 河北医科大学研究生学院,河北,石家庄,050000
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.08.009
  CLC： R737.25
- Published Online：03 September 2020，
  
  Published：03 September 2020
- 稿件说明：
移动端阅览
樊　博, 齐　盼, 苏建志, 卫书飞, 张　轩, 张爱莉 . 河北医科大学第四医院前列腺癌患者的基线特征与生存分析[J]. 中国癌症杂志, 2020, 30(8): 620-625.

樊　博, 齐　盼, 苏建志, et al. Baseline characteristics and survival analysis of patients with prostate cancer in the Fourth Hospital of Hebei Medical University[J]. China Oncology, 2020, 30(8): 620-625.
樊　博, 齐　盼, 苏建志, 卫书飞, 张　轩, 张爱莉 . 河北医科大学第四医院前列腺癌患者的基线特征与生存分析[J]. 中国癌症杂志, 2020, 30(8): 620-625. DOI： 10.19401/j.cnki.1007-3639.2020.08.009.

樊　博, 齐　盼, 苏建志, et al. Baseline characteristics and survival analysis of patients with prostate cancer in the Fourth Hospital of Hebei Medical University[J]. China Oncology, 2020, 30(8): 620-625. DOI： 10.19401/j.cnki.1007-3639.2020.08.009.

摘要

背景与目的：近年来，前列腺癌发病率逐年增高，但前列腺癌筛查工作仍不全面，国内前列腺癌数据库也相对匮乏。分析河北医科大学第四医院前列腺癌患者的基线特征、治疗以及生存情况等数据，为河北及周边地区前列腺癌的诊治提供参考。方法：回顾性分析2008年1月—2018年12月在河北医科大学第四医院泌尿外科就诊的857例前列腺癌患者信息，分析初次就诊时非转移性（M

）和转移性（M

）前列腺癌患者的基线特征、治疗方案和生存情况。对随访数据采用Kaplan-Meier法绘制生存曲线，并用log-rank检验比较两组之间生存率差异。结果：纳入基线统计的患者共计857例，中位年龄71岁，797例存在前列腺特异性抗原（prostate-specific antigen，PSA）记录，689例存在Gleason评分记录。412例M

患者和445例M

患者中，PSA≥100 ng/mL的患者分别占11.1%（44/397）和57.3%（229/400），Gleason评分≥8分的患者分别占46.9%（166/354）和63.9%（214/335）。纳入随访分析的患者共计606例，患者生存395例，死亡211例，其中182例死于肿瘤进展。M

和M

患者5年生存率分别为63.2%（76/120）和41.3%（102/247），M

和M

患者的中位生存期分别为85和 47个月（P＜0.01）。此外，在所有采用传统内分泌治疗［雄激素剥夺治疗（androgen deprivation therapy，ADT）或联合雄激素阻断治疗（combined androgen blockade，CAB）］的M

患者和高危转移性激素敏感性前列腺癌（metastatic hormone-sensitive prostate cancer，mHSPC）患者中，中位PSA进展时间（time to PSA progression，TTPP）分别为18和17个月。内分泌治疗初诊M

患者的中位TTPP为25个月。12例影像学检测未发现远处转移的去势抵抗性前列腺癌（non-metastatic castrate-resistant prostate

cancer，NM-CRPC）患者，中位无转移生存期（metastasis-free survival，MFS）仅为16个月。结论：前列腺癌患者的年龄、PSA及Gleason评分偏高，多数患者在治疗时有转移，5年生存率偏低，因此应重视和加强前列腺癌的筛查工作。在接受内分泌治疗的M

患者进展为转移性去势抵抗性前列腺癌（metastatic castrate-resistant prostate cancer，mCRPC）的时间较短，此外，接受内分泌治疗的M

患者进展至NM-CRPC后，进展为mCRPC或死亡的时间也非常短，未来对于M

和NM-CRPC患者应采取更为积极的治疗，以延缓病情进展到mCRPC阶段。

Abstract

Background and purpose: In recent years

the incidence of prostate cancer has increased year by year

the screening of prostate cancer is still not comprehensive

and the domestic prostate cancer database is also relatively scarce. The purpose of this study was to analyze baseline characteristics

treatment and survival of prostate cancer patients from the Fourth Hospital of Hebei Medical University

in order to provide reference for the diagnosis and treatment of prostate cancer in Hebei and its surrounding areas. Methods: The information of 857 patients with prostate cancer treated in the Department of Urology

the Fourth Hospital of Hebei Medical University from Jan. 2008 to Dec. 2018 were analyzed retrospectively. Patients with non-metastatic prostate cancer (M

) or distant metastatic prostate cancer (M

) were analyzed for baseline characteristics

treatment and survival at the time of first visit. Kaplan-Meier method was used to draw survival curves

and log-rank test was used to compare survival rates between the two groups. Results: A total of 857 patients were included in the baseline statistics. Among those

797 cases had prostate-specific antigen (PSA) record

and 689 cases had Gleason score record. The median age of all patients was 71 years. Among 412 M

patients and 445 M

patients

11.1% (44/397) and 57.3% (229/400) patients had a PSA of ≥100 ng/mL respectively

as well as 46.9% (166/354) and 63.9% (214/335) patients had a Gleason score of ≥8 respectively. A total of 606 patients were included in the follow-up analysis

395 patient

s survived

and 211 patients died. A total of 182 patients died of tumor progression. The 5-year survival rates of M

and M

patients were 63.2% (76/120) and 41.3% (102/247) respectively. The median overall survival time of M

and M

patients were 85 months and 47 months (P0.01) respectively. Additionally

in all M

patients and high-risk metastatic hormone-sensitive prostate cancer (mHSPC) patients using traditional endocrine therapy (androgen deprivation therapy

ADT or combined androgen blockade

CAB)

the median time to PSA progression (TTPP) was 18 months and 17 months respectively. The median TTPP of M

patients treated with endocrine therapy was 25 months. For 12 patients with castrate-resistant prostate cancer and no detectable clinical metastasis using imaging examinations (non-metastatic castrate-resistant prostate cancer

NM-CRPC)

the median metastasis-free survival (MFS) time was only 16 months. Conclusion: Patients with prostate cancer had advanced age

elevated PSA level and high Gleason score. Most of the patients had metastasis at the time of treatment. The 5-year survival rate was low. Therefore

the prostate cancer screening should be valued and strengthened. M 1 patients treated with endocrine therapy had a short time to progress to metastatic castrate-resistant prostate cancer (mCRPC). Moreover

after M

patients treated with endocrine therapy progressed to NM- CRPC

the time for progression to mCRPC or death was also very short. In the future

and NM-CRPC patients will need more aggressive treatments in order to delay the progression to the mCRPC.

关键词

Keywords

references

Views

3456

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

The research on construction of the spontaneous prostate tumor and breast cancer model of Pten^fl/fl;Trp53^fl/fl;Pbsn-iCre⁺ transgenic mouse

Survival analysis of female breast cancer in Shanghai: a population-based study from 2002 to 2017

Chinese expert consensus on perioperative integrated rehabilitation for radical prostatectomy (2024 edition)

Expert consensus of ¹⁷⁷Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)

Related Author

Hao LIU

Junjie SU

Shiyong XIN

Jiachen WU

Lina HE

Xinru TANG

Shuang TANG

Chunxiao WU

Related Institution

Department of Urology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology

College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology

Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

College of Life Sciences, Inner Mongolia University, Hohhot 010000, Inner Mongolia Autonomous Region

Division of Noncommunicable Diseases and Injury, Shanghai Municipal Center for Disease Control and Prevention

AI问答

⁰